Groupe Hospitalier De La Region De Mulhouse Et Sud Alsace
- Address
- lock Available on a paid plan
Bacterial Infections and Mycoses
The department is conducting research on Mycobacterium xenopi pulmonary infection, aiming to improve treatment outcomes through innovative inhaled antibiotic approaches.
- Evaluation of an inhaled liposomal amikacin formulation
- Assessment of 3‑month sputum conversion rates
- Comparison with standard antibiotic regimens
- Monitoring of safety and tolerability in respiratory patients
These studies are carried out at Groupe Hospitalier De La Region De Mulhouse Et Sud Alsace, contributing to better management of difficult‑to‑treat bacterial lung infections.
Hemic and Lymphatic Diseases
Researchers are exploring new therapeutic combinations for myelofibrosis, focusing on disease control in patients who have not received prior treatment.
- Combination of a nuclear export inhibitor with a JAK pathway blocker
- Impact on symptom burden and spleen size
- Evaluation of treatment‑naïve patient response
- Long‑term safety monitoring
The work at this Mulhouse hospital aims to expand options for patients with advanced hematologic disorders.
Nervous System Diseases
The pneumology unit is investigating an oral agent for Diabetic Peripheral Neuropathic Pain, with the goal of reducing pain intensity and improving daily function.
- Measurement of pain score changes over time
- Patient‑reported outcome assessments
- Safety and tolerability in a diabetic population
- Comparison against placebo treatment
This research provides hope for individuals living with chronic neuropathic pain associated with diabetes.
Immune System Processes
A study targeting Systemic Lupus Erythematosus is evaluating a novel oral therapy designed to modulate immune activity and lower disease activity scores.
- Assessment of clinical disease activity indices
- Evaluation of immune pathway modulation
- Impact on quality of life measures
- Safety profile in adult participants
Conducted at the Mulhouse research site, this work seeks to broaden therapeutic choices for patients with autoimmune disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 17 therapeutic areas and 15 of 168 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 162 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 32 by active trials.
lock +31 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Groupe Hospitalier De La Region De Mulhouse Et Sud Alsace
lock Showing 1 of 80 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter randomized, double-blind, placebo-controlled Phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics and target engagement of GSK3858279 in adult participants with chronic Diabetic Peripheral Neuropathic Pain (DPNP) / NEPTUNE-17. | Glaxosmithkline Research & Development Limited | Phase II | Not Recruiting | Dec 2023 | Oct 2024 |
IMP list
lock Showing 1 of 168 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 11 | Unknown | 2019-07-22 | 2025-11-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.